Hyperglycemia exacerbates colon cancer malignancy through hexosamine biosynthetic pathway

Andréia Vasconcelos-dos-Santos(Fundação Carlos Chagas), Hector F.B.R. Loponte(Fundação Carlos Chagas), Natália Rodrigues Mantuano(Fundação Carlos Chagas), Isadora de Araújo Oliveira(Fundação Carlos Chagas), Iron F. De Paula(Universidade Federal do Rio de Janeiro), Leonardo K. Teixeira(Instituto Nacional de Câncer - INCA), Julio Cesar Madureira de‐Freitas‐Junior(Universidade Federal do Rio de Janeiro), Kátia C. Gondim(Universidade Federal do Rio de Janeiro), Norton Heise(Fundação Carlos Chagas), Ronaldo Mohana‐Borges(Fundação Carlos Chagas), José Andrés Morgado‐Díaz(Universidade Federal do Rio de Janeiro), Wagner B. Dias(Fundação Carlos Chagas), Adriane R. Todeschini(Fundação Carlos Chagas)
Oncogenesis
March 20, 2017
Cited by 112Open Access
Full Text

Abstract

Hyperglycemia is a common feature of diabetes mellitus, considered as a risk factor for cancer. However, its direct effects in cancer cell behavior are relatively unexplored. Herein we show that high glucose concentration induces aberrant glycosylation, increased cell proliferation, invasion and tumor progression of colon cancer. By modulating the activity of the rate-limiting enzyme, glutamine-fructose-6-phosphate amidotransferase (GFAT), we demonstrate that hexosamine biosynthetic pathway (HBP) is involved in those processes. Biopsies from patients with colon carcinoma show increased levels of GFAT and consequently aberrant glycans' expression suggesting an increase of HBP flow in human colon cancer. All together, our results open the possibility that HBP links hyperglycemia, aberrant glycosylation and tumor malignancy, and suggest this pathway as a potential therapeutic target for colorectal cancer.


Related Papers

No related papers found

Powered by citation graph analysis